News | May 31, 2025
QMS Medical Allied Services posts 134.36% jump in consolidated PAT in Q4 FY25
Operating income on consolidated basis increased by 38.10% at Rs 44.58 crore in Q4 FY25
Operating income on consolidated basis increased by 38.10% at Rs 44.58 crore in Q4 FY25
Pivotal results from the Phase 3 Breakwater trial showed 51% risk reduction in death compared to standard-of-care treatment
Manageable safety profile and encouraging antitumor activity observed for MK-1084 in KANDLELIT-001, both as a monotherapy and in studied combinations
The company also announced results for the third quarter, reporting sales at Rs. 992 crore, flat versus year ago
The decision to withdraw the BLA is based on topline overall survival (OS) results from the confirmatory HERTHENA-Lung02 Phase 3 trial where OS did not meet statistical significance
This is specifically for the evaluation of medicines that, if approved, would provide a significant improvement in the safety or effectiveness of the treatment, prevention, or diagnosis of a serious condition
MANEUVER met all five key secondary endpoints, with statistically significant and clinically meaningful improvements in pain, stiffness, range of motion, physical function, and decrease in tumor volume
The company reported sustained increase in formulations' share despite slowdown in productivity of Gagillapur facility
During the quarter, US formulations revenue increased by 13.5 per cent YoY to Rs. 4,072 crore
The company recorded its quarterly consolidated revenue from operations at Rs. 61.22 crore in Q4 FY25
Subscribe To Our Newsletter & Stay Updated
